Luminex Q3 Revenues Soar on Strong xMAP Sales | GenomeWeb
NEW YORK (GenomeWeb News) – Luminex yesterday reported a 55 percent increase in third-quarter revenues, driven by robust sales of its flagship xMAP technology.
 
Total revenues for the three months ended Sept. 30 rose to $19.4 million from $12.5 million in the third quarter of 2006.
 
The quarter’s results included revenue from Tm Bioscience, which Luminex acquired in March and renamed Luminex Molecular Diagnostics.
  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.